Streetbeat News

Revenues

ALKS

Alkermes projects its fiscal year 2024 revenues to be between $1.5 billion and $1.6 billion, aligning closely with the consensus estimate of $1.52 billion. Additionally, the company anticipates achieving a 30% EBITDA margin in 2024.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:19 pm

WULF

TeraWulf has announced surpassing a self-mining hashrate of 7.6 Eh/s and repaid $22 million of its term loan, extending the cash flow sweep to maturity.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:19 pm

IRWD

Ironwood Pharmaceuticals projects its FY24 sales to range from $435M to $455M, which is below the estimated $462.82M. Additionally, the company anticipates its FY24 adjusted EBITDA to exceed $150M.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:13 pm

AGEN

Ginkgo Bioworks and SaponiQx, a subsidiary of Agenus Inc (NASDAQ: AGEN), have been awarded a 5-year contract by the MCDC, worth up to $31M, to discover and manufacture next-generation vaccine adjuvants using generative molecular design.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:10 pm

IRWD

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported Q4 sales of $117.55M, slightly above the $117.48M estimate, marking a 9.66% increase from the previous year. The company also generated $35.8M in cash from operations during Q4.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:10 pm

GTX

Garrett Motion forecasts its FY24 net sales to reach $3.87 billion.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:07 pm

HBI

HanesBrands forecasts FY24 net sales from continuing operations to be between $5.35B and $5.47B, which is below the estimated $5.578B. The company also expects adjusted EPS from continuing operations to range from $0.42 to $0.48, aligning with the lower end of the estimated $0.48.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:07 pm

APPN

Appian provided its Q1 and FY24 earnings and revenue forecasts, with both falling short of analysts' expectations. For Q1, it expects adjusted EPS between $(0.21) and $(0.16), compared to the $(0.17) estimate, and revenue between $148.0M and $150.0M, against the $150.84M estimate. For FY24, the adjusted EPS forecast is between $(0.73) and $(0.66), versus the $(0.60) estimate, with revenue expected to be between $615.0M and $617.0M, slightly below the $618.17M estimate.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:06 pm

IRDM

Iridium Communications (IRDM) forecasts FY24 service revenue growth of 4%-6% from $584.5M in FY23, with OEBITDA expected between $460M-$470M, compared to $463.1M in FY23. The company also anticipates cash taxes under $10M annually through 2024-2026, aiming for net leverage below 2.5 times OEBITDA between 2026-2029, and under 2.0 by decade's end.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:06 pm

BPMC

Blueprint Medicines projects its global net product revenues for AYVAKIT to be in the range of $360M-$390M in 2024, indicating a positive outlook for the company's financial performance.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:06 pm